Download
s00432-020-03361-0.pdf 1,15MB
WeightNameValue
1000 Titel
  • Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy
1000 Autor/in
  1. Markus, M. |
  2. Abendroth, A. |
  3. Noureddine, R. |
  4. Paul, A. |
  5. Breitenbuecher, S. |
  6. Virchow, I. |
  7. Schmid, K. W. |
  8. Markus, P. |
  9. Schumacher, B. |
  10. Wiesweg, M. |
  11. Wendling, J. |
  12. Mende, B. |
  13. Siveke, J. T. |
  14. Schuler, M. |
  15. Kasper, Stefan |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-08-25
1000 Erschienen in
1000 Quellenangabe
  • 147(2):579-591
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00432-020-03361-0 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817578/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!The prognosis of patients with advanced pancreatic ductal adenocarcinoma (PDAC) remains dismal. New cytotoxic agents such as nab-paclitaxel and liposomal irinotecan (nal-Iri) have extended the armamentarium of therapeutic options in the last years. Nowadays, sequential therapeutic strategies with moderately toxic chemotherapeutic protocols can be administered to the patients. However, prognostic and predictive biomarkers are still missing to identify those patients, which profit most from a 'continuum of care' concept rather than receiving intensive first-line protocols such as FOLFIRINOX. To this end, we retrospectively evaluated the impact of the systemic inflammation as one essential hallmark of cancer in patients with advanced PDAC treated with sequential systemic.!##!Methods!#!A cohort of 193 PDAC patients treated at our center from January 2005 to August 2011 were retrospectively evaluated for the following systemic inflammatory response (SIR) markers: neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR) C-reactive protein (CRP), and the modified Glasgow Prognostic Score (mGPS). SIR markers were correlated with clinico-pathological findings, response to chemotherapy and overall survival (OS) using Kaplan-Meier curves and Cox proportional models.!##!Results!#!All evaluated SIR markers were significantly associated with OS in patients with metastatic disease but not in patients with locally advanced PDAC. Interestingly, all SIR markers were only prognostic in patients not receiving antibiotics as surrogate marker for systemic bacterial infections. Based on the evaluated SIR markers, we propose a new Systemic Inflammation Score (SIS), which significantly correlated with reduced OS (HR: 3.418 (1.802-6.488, p < 0.001)) and the likelihood of receiving further-line systemic therapies (p = 0.028).!##!Conclusion!#!Routinely assessed SIR biomarkers have potential to support therapeutic decision making in patients with metastatic PDAC.
1000 Sacherschließung
lokal Carcinoma, Pancreatic Ductal/immunology [MeSH]
lokal Female [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Neutrophils [MeSH]
lokal Aged [MeSH]
lokal Adult [MeSH]
lokal Original Article – Clinical Oncology
lokal Humans [MeSH]
lokal Inflammation
lokal Lymphocytes [MeSH]
lokal Carcinoma, Pancreatic Ductal/mortality [MeSH]
lokal Palliative Care [MeSH]
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Pancreatic Neoplasms/drug therapy [MeSH]
lokal Prognosis
lokal Pancreatic Neoplasms/immunology [MeSH]
lokal Carcinoma, Pancreatic Ductal/drug therapy [MeSH]
lokal Male [MeSH]
lokal Inflammation/complications [MeSH]
lokal Prognosis [MeSH]
lokal C-Reactive Protein/analysis [MeSH]
lokal Pancreatic Neoplasms/mortality [MeSH]
lokal Pancreatic cancer
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/TWFya3VzLCBNLg==|https://frl.publisso.de/adhoc/uri/QWJlbmRyb3RoLCBBLg==|https://frl.publisso.de/adhoc/uri/Tm91cmVkZGluZSwgUi4=|https://frl.publisso.de/adhoc/uri/UGF1bCwgQS4=|https://frl.publisso.de/adhoc/uri/QnJlaXRlbmJ1ZWNoZXIsIFMu|https://frl.publisso.de/adhoc/uri/VmlyY2hvdywgSS4=|https://frl.publisso.de/adhoc/uri/U2NobWlkLCBLLiBXLg==|https://frl.publisso.de/adhoc/uri/TWFya3VzLCBQLg==|https://frl.publisso.de/adhoc/uri/U2NodW1hY2hlciwgQi4=|https://frl.publisso.de/adhoc/uri/V2llc3dlZywgTS4=|https://frl.publisso.de/adhoc/uri/V2VuZGxpbmcsIEou|https://frl.publisso.de/adhoc/uri/TWVuZGUsIEIu|https://frl.publisso.de/adhoc/uri/U2l2ZWtlLCBKLiBULg==|https://frl.publisso.de/adhoc/uri/U2NodWxlciwgTS4=|https://orcid.org/0000-0002-5947-8733
1000 Hinweis
  • DeepGreen-ID: b47c7ad6812743ab9e7d0d790f303b8d ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6469366.rdf
1000 Erstellt am 2023-11-17T22:14:47.057+0100
1000 Erstellt von 322
1000 beschreibt frl:6469366
1000 Zuletzt bearbeitet 2023-12-01T09:42:24.635+0100
1000 Objekt bearb. Fri Dec 01 09:42:24 CET 2023
1000 Vgl. frl:6469366
1000 Oai Id
  1. oai:frl.publisso.de:frl:6469366 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source